Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Antitumor effects of erlotinib in combination with berberine in A431 cells

Fig. 2

Berberine combined with erlotinib inhibited the EGFR signaling pathway in A431 cells. (a) A431 cells were treated with a range of BBR doses for 48 h. Phosphorylation of EGFR, AKT, and ERK were evaluated using western blot. The p-EGFR, p-ERK1/2 p-AKT, EGFR, ERK1/2, AKT, and β-tubulin proteins were separated using 8% SDS-PAGE. Each experiment was performed 3 times independently. (c) A431 cells were treated with BBR (2.5 µg/mL) combined with erlotinib (0.01µM) for 30 min. Phosphorylation of each protein was evaluated using western blot. Each experiment was also performed 3 times independently. (b, d) Quantification of EGFR and downstream signaling proteins. Data were analyzed using one-way ANOVA, #P < 0.05; ##P < 0.01; ###P < 0.001 vs. control. *P < 0.05; **P < 0.01; ***P < 0.001 vs. combination-therapy group

Back to article page